Edesa Biotech, Inc. (NASDAQ:EDSA – Get Rating) – Equities research analysts at HC Wainwright upped their Q3 2023 earnings estimates for shares of Edesa Biotech in a research note issued on Wednesday, May 24th. HC Wainwright analyst V. Bernardino now expects that the company will earn ($0.12) per share for the quarter, up from their prior estimate of ($0.13). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Edesa Biotech’s Q4 2023 earnings at ($0.13) EPS, FY2023 earnings at ($0.50) EPS and FY2024 earnings at ($0.88) EPS.
Edesa Biotech Stock Performance
NASDAQ EDSA opened at $0.91 on Friday. Edesa Biotech has a one year low of $0.76 and a one year high of $2.81. The company’s 50 day moving average price is $1.01 and its 200 day moving average price is $1.27. The firm has a market capitalization of $18.74 million, a price-to-earnings ratio of -1.44 and a beta of 0.43.
Institutional Trading of Edesa Biotech
About Edesa Biotech
Edesa Biotech, Inc is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness.
- Get a free copy of the StockNews.com research report on Edesa Biotech (EDSA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.